Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML2950

Sigma-Aldrich

E7820

≥98% (HPLC)

Synonym(s):

3-Cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide, 3-Cyano-N-(3-cyano-4-methyl-1H-indole-7-yl)benzensulfonamide, E 7820, NSC 719239

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C17H12N4O2S
CAS Number:
289483-69-8
Molecular Weight:
336.37
MDL number:
MFCD09833234
UNSPSC Code:
12352200
NACRES:
NA.77

ligand

E7820

Quality Level

100

Assay

≥98% (HPLC)

form

powder

reaction suitability

reagent type: ligand

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

InChI

1S/C17H12N4O2S/c1-11-5-6-15(17-16(11)13(9-19)10-20-17)21-24(22,23)14-4-2-3-12(7-14)8-18/h2-7,10,20-21H,1H3

InChI key

LWGUASZLXHYWIV-UHFFFAOYSA-N

Related Categories

Biochem/physiol Actions

E7820 (NSC 719239) is an orally available anticancer and antiangiogenic agent that inhibits VEGF-2 or FGF-2-induced tube formation of HUVEC cells through the suppression of integrin α2. E7820 promotes selective proteasomal degradation of the U2AF-related splicing factor CAPERα (coactivator of activating protein-1 and estrogen receptors) by ubiquitination and degradation via CRL4DCAF15.

related product

Product No.
Description
Pricing

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ron J Keizer et al.
The AAPS journal, 13(2), 230-239 (2011-03-10)
E7820 is an orally active inhibitor of α(2)-integrin mRNA expression, currently tested in phases I and II. We aimed to evaluate what levels of inhibition of integrin expression are needed to achieve tumor stasis in mice, and to compare this
Ken Ito et al.
Cancer science, 105(8), 1023-1031 (2014-05-21)
Most non-small-cell lung cancers (NSCLCs) harboring activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to EGFR tyrosine kinase inhibitors (EGFR-TKIs); however, they invariably develop resistance to these drugs. E7820 is an angiogenesis inhibitor that decreases integrin-α2
Taisuke Uehara et al.
Nature chemical biology, 13(6), 675-680 (2017-04-25)
Target-protein degradation is an emerging field in drug discovery and development. In particular, the substrate-receptor proteins of the cullin-ubiquitin ligase system play a key role in selective protein degradation, which is an essential component of the anti-myeloma activity of immunomodulatory

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service